Fidia S.p.a.

M.u.r.s.t. (italian Ministry for Universities and Scientific and

Zanichelli Ricerche S.r.l.

Zanichelli Richerche S.r.i.

M.u.r.s.t. Italian Ministry for Universities and Scientific and Technological Research

Aurelio Romeo

Francesco Della Valle

Lanfranco Callegaro

Silvana Lorenzi

Gino Toffano

Gabriella Calderini

Alessandro Rastrelli

Gunter Kirschner

Franco Dorigatti

Hari Manev

Luca Benedetti

Carlo Chizzolini

Laura Facci

Bruno Silvestrini

Alberta Leon

Stephen Drake Skaper

Giorgio Favaro

Francesco D Valle

Gianpaolo Menon

Alberto Perbellini

Martino Trimarco

A tomato composition obtained from tomato juice having the following composition in percentage by weight: dry residue&#x3e;20% up to 99%, water&#x3c;80% down to 1%; 100% being the sum of the two components, wherein the among of water insoluble solids in the dry residue ranges in percentage by weight from 18% to 70%.

Concentrated tomato products

A process for treating tomato concentrates obtainable by concentration by evaporation, having a dry residue in percentage by weight higher than 15%, generally at least of about 18%, comprising the following steps: I) mixing of the tomato concentrate (component a)) with water (component b)); II) liquid separation by a separation solid-liquid apparatus, wherein the mass to be filtered is maintained under a slow stirring; III) addition of water and/or serum to the solid mass obtained in II).

Tomato products and process for their preparation

Tomato products obtained from tomato juice or tomato passata having the following composition in percentage by weight:

Tomato products

The present invention refers to pharmaceutical compositions containing monosialoganglioside GM or a derivative thereof, namely, the inner ester AGF and the methyl ester AGF4, suitable for the treatment of Parkinson's disease. A further object of the present invention is a therapy for Parkinson's disease based on the associated administration of the aforesaid compounds and, in addition, the N-dichloroacetyl lyso GM (LIGA 20) with known pharmaceuticals active in the aforesaid treatment, in particular with L-dopa and/or BDNF.

Pharmaceutical compositions containing monosialoganglioside GM1 or derivative thereof suitable for the treatment of parkinson's disease

The present invention involves compositions for use as granular bone replacements. The compositions of the present invention are comprised of hyaluronic acid esters or salts of hyaluronic acid in association with a pharmacologically active compound wherein the molecular weight of the hyaluronic acid is below 250,000 and either artificial or natural bone granules. The present invention further involves a method of promoting the growth or repair of damaged or defective bones in either humans or animals using the compositions of hyaluronic acid derivatives and bone granules.

Biomaterials for bone replacements

Novel N-acyl-lysogangliosides obtained from gangliosides by deacyation of the ceramide group, wherein the acyl group is derived from an aliphatic acid having from 2 to 24 carbon atoms, substituted by one or more polar groups. The N-acyl-lysogangliosides of the invention exhibit an inhibiting action on protein-kinase C activation and, thus, can be utilized in therapies for various pathologies of the nervous system.

Lysoganglioside derivatives

Pharmaceutical preparations are described, comprised of salts of hyaluronic acid with a basic anesthetic containing aliphatics and/or amino groups, particularly salts with benzydamine or bupivacaine.

Pharmaceutical preparations comprised of salts of hyaluronic acid with local anaesthetics

The present invention is directed to a microsphere for the controlled release of a biologically active molecule which comprises a biologically active molecule and an ester of hyaluronic acid or mixtures of said esters of hyaluronic acids, and wherein said biologically active molecule is surrounded by or adhered to said ester of hyaluronic acid, and wherein said microsphere has a diameter of between 1 .mu.m to 100 .mu.m.

Process for the preparation of microspheres containing biologically

Two pharmaceutically useful fractions of hyaluronic acid are obtained comprising a first fraction with a molecular weight between 50,000 and 100,000 which is useful for wound healing, and a second fraction having a molecular weight between 500,000 and 730,000 which is useful for intraocular and intraarticular injections.

Hyaluronic acid fractions having pharmaceutical activity, and

The present invention is drawn to medical devices comprising biodegradable guide channels for use in the repair and regeneration of nerve tissue. The guide channels of the present invention comprise interlaced threads imbedded in a matrix, wherein both the matrix and the threads comprise biocompatible and bioabsorbable esters of hyaluronic acid. The matrix of the present invention further optionally comprises biologically or pharmacologically active factors in association with the guide channels.

Biodegradable guide channels comprised of esters of hyaluronic acid for

O-sulfated gangliosides and lyso-ganglioside derivatives

Sulfated lyso-ganglioside derivatives

Novel derivatives of lysophingolipids free from sialic acids which are N-acyllysosphingolipids having one of the two formulae: ##STR1## in which -A- stands for the group --CH.dbd.CH-- or --CH.sub.2 --CH.sub.2 --, n.sub.1 is a whole number of between 6 and 18, n.sub.2 is a whole number of between 11 and 15, X is a hydrogen atom or the residue of a monosaccharide or a disaccharide or phosphorylcholine and R represents an alkyl radical derived from a saturated or unsaturated aliphatic carboxylic acid having from 2 to 24 carbon atoms substituted by one or more polar groups. The lysosphingolipid derivatives of the invention exhibit an inhibiting action on protein-kinase C activation and, thus, can be utilized in therapies for various pathologies of the nervous system.

Growing community of inventors

Rome, Italy

Aurelio Romeo